Athenex Ruling Helps Clarify FDA Drug Compounding Policy

By Nathan Brown, Howard Sklamberg, Eli Tomar and Sudhana Bajracharya ( August 9, 2019, 3:49 PM EDT) -- On Aug. 1, 2019, the U.S. District Court for the District of Columbia affirmed the U.S. Food and Drug Administration's decision to exclude the bulk drug substance vasopressin from the agency's List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act, or 503B bulks list, in Athenex Pharma Solutions LLC v. Azar II.[1]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as